GlaxoSmithKline is continuing its investment in emerging markets with the acquisition of Bristol-Myers Squibb Pakistan and certain associated trademarks for some US$36.5 million (£24.6 million)
Glaxo continues emerging markets push
GlaxoSmithKline is continuing its investment in emerging markets with the acquisition of Bristol-Myers Squibb Pakistan and certain associated trademarks for some US$36.5 million (£24.6 million)
